BMJ Evidence-Based Medicine 28(4):213-217
Ohkubo, M., Ohta, K., Inoue, K
Talasaz A, Sadeghipour P, Ortega-Paz L, Kakavand H, Aghakouchakzadeh M, Beavers C, Fanikos J, Eikelboom J, Siegal D, Monreal M, Jimenez D, Vaduganathan M, Castellucci L, Cuker A, Barnes G, Connors J, Secemsky E, Van Tassell B, De Caterina R, Kurlander J, Aminian A, Piazza G, Goldhaber S, Moores L, Middeldorp S, Kirtane A, Elkind M, Angiolillo D, Konstantinides S, Lip G, Stone G, Cushman M, Krumholz H , Mehran R, Bhatt D, Bikdeli B
The distinctive value of PET imaging lies in its capacity to provide non-invasive, visual evidence of neuroinflammation, thereby directly linking peripheral immune activation with central clinical manifestations, such as brain fog and cognitive decline, while also revealing the heterogeneity within patient populations
Colombia covers liraglutide for high-BMI cases but imposes multi-step prior authorization